J Thaddeus Beck MD FACP

Clinical Trials

• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer Start of enrollment: 2006 Apr 01

  Completed

  Phase 2

• Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients Start of enrollment: 2007 Apr 01

  Completed

  Phase 1

• Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma Start of enrollment: 2007 Nov 01

  Completed

  Phase 1

• Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy Start of enrollment: 2006 Sep 01

  Terminated

  Phase 2

• Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2011 Mar 22

  TERMINATED

  PHASE1

• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01

  Terminated

  Phase 3

• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20

  Completed

  Phase 3

• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 16

  Completed

  Phase 3

• PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12

  Active, not recruiting

  Phase 2, Phase 3

• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12

  ACTIVE_NOT_RECRUITING

  PHASE3

• Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy Start of enrollment: 2013 Oct 28

  Terminated

• A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05

  Completed

  Phase 1

• Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19

  ACTIVE_NOT_RECRUITING

  PHASE2

• Vaccination of High Risk Breast Cancer Patients Start of enrollment: 2015 Jan 14

  COMPLETED

  PHASE1, PHASE2

• RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31

  Completed

  Phase 1, Phase 2

• Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) Start of enrollment: 2015 Aug 10

  Completed

  Phase 2

• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Start of enrollment: 2015 Jul 23

  COMPLETED

  PHASE3

• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10

  ACTIVE_NOT_RECRUITING

  PHASE3

• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Start of enrollment: 2015 Dec 21

  Completed

  Phase 3

• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Start of enrollment: 2016 Apr 27

  COMPLETED

  PHASE2

• Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Start of enrollment: 2016 Jun 29

  Terminated

  Phase 1

• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Start of enrollment: 2016 May 19

  Terminated

  Phase 3

• Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Start of enrollment: 2016 Jun 14

  Completed

  Phase 1, Phase 2

• Vaccination of Triple Negative Breast Cancer Patients Start of enrollment: 2019 Jan 25

  COMPLETED

  PHASE1, PHASE2

• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Start of enrollment: 2016 Nov 28

  Terminated

  Phase 3

• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18

  ACTIVE_NOT_RECRUITING

  PHASE3

• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Start of enrollment: 2017 Jan 16

  Completed

  Phase 4

• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Start of enrollment: 2020 Jul 16

  ACTIVE_NOT_RECRUITING

  PHASE3

• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09

  COMPLETED

  PHASE1, PHASE2

  Roles: Contact

• Join now to see all